To the Editor, Targeting B-cell maturation antigen (BCMA) has transformed the relapsed/refractory multiple myeloma (RRMM) landscape with unprecedented overall survival (OS) outcomes versus standard-of-care triplet regimens. Belantamab mafodotin, an anti-BCMA antibody-drug conjugate, has a multimodal mechanism of action involving minimal immunosuppression and no evidence of induction of T-cell exhaustion [1, 2].
Julia Boyle
As seen in:
Nature,
Wiley Online Library,
PLOS ONE,
MDPI,
SAGE Publishing,
BioRxiv,
Dove Medical Press,
MDEdge,
Pharmacy Times
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Julia
Contact Julia, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack